GSK plc stock is downgraded due to litigation risks, weak sales, and market pressures, dividend yield remains a bright spot. Click for more on GSK stock.

The FDA flagged at least five cases of severe or very severe RSV lower respiratory tract infections in infants immunized with ...

Failed to fetch dynamically imported module: https://finance.yahoo.com/assets/_app/immutable/nodes/91.DyCR3BqR.js ...

GSK expands the licensing deal with Zhifei to market its shingles vaccine in China for an additional eight years till 2034.

Under the revised agreement, the two have taken their RSV commitment a step forward as Zhifei agrees to engage exclusively ...

China's Zhifei will pay GSK about 2.3 billion pounds ($2.9 billion) for the exclusive rights to distribute GSK's shingles ...

GSK said on Thursday it had expanded its agreement with China's largest vaccine company Zhifei to explore a potential ...

Although the FDA has expanded approvals for two respiratory syncytial virus (RSV) vaccines to include high-risk young and ...

Learn about this vaccine that protects against a common seasonal virus that can sometimes cause severe disease, with info on ...

Head-to-head clinical results indicate a potential best-in-class combined efficacy & safety profile of non-adjuvanted bivalent RSV vaccine candidate ... GSK's AS01E-adjuvanted AREXVY in older ...